English summaries translate the Chinese website. Links open the original source articles, which may be in Chinese.
Company News
R&D progress, marketing approval, cooperation and announcements - read Bio-Thera's latest public information by time.
Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026
GUANGZHOU, China – October 2026 – Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company...
Read more
August2026
1 item-
Avalon Pharma and Bio-Thera Execute Exclusive Commercialization Agreement for BAT2406, a Proposed Dupixent? Biosimilar, for MENA
Riyadh, Saudi Arabia / Guangzhou, China – August 18, 2026 – Avalon Pharma (Middle East Pharmaceutical Industries Company...
July2026
1 item-
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8013, an Antibody Drug Conjugate Targeting CD25 for the Treatment of Advanced Solid Tumors
Guangzhou, China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, t...
May2026
1 item-
Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi? and Simponi Aria?; Accord BioPharma to Commercialize IMMGOLIS? (golimumab-sldi) and IMMGOLIS INTRI? (golimumab-sldi) in the United States
GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...
March2026
1 item-
Bio-Thera Solutions Announces Further Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi? (golimumab), through Exclusive Commercialization and License Agreement in India
GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...
February2026
3 items-
Bio-Thera Solutions Announces NMPA Accepts New Drug Application for BAT4406F, an ADCC-enhanced fully humanized anti-CD20 monoclonal antibody
Guangzhou – Feb 26, 2025 – Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing...
-
STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi
? European Commission grants approval for Gotenfia?, a golimumab biosimilar to Simponi? that was developed by Bio-Thera ...
-
Bio-Thera and Avalon Pharma Execute Exclusive Commercialization Agreement for BAT3306, a Proposed Keytruda? Biosimilar for Saudi Arabia and MENA
Guangzhou, China/Riyadh, Saudi Arabia – February 3, 2026 – Bio-Thera Solutions (688177:SH; “Bio-Thera”), a commercial-st...
December2025
1 item-
Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion
?Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia?developed by Bio-Th...
November2025
2 items-
Bio-Thera Solutions Expands Partnership with Dr. Reddy’s through an Exclusive Commercialization and License Agreement for BAT2306, a Proposed Biosimilar Candidate to Cosentyx? (Secukinumab), in Southeast Asia
Guangzhou, China; November 10, 2025: Bio-TheraSolutions (688177:SH; “Bio-Thera”), a commercial-stage biopharmaceuticalco...
-
Bio-Thera Solutions Announces the Launch of STARJEMZA? (ustekinumab-hmny) in the United States
GUANGZHOU,China - Bio-Thera Solutions (688177.SH), a commercial-stage biopharmaceutical companydeveloping innovative the...
October2025
1 item-
Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi? (golimumab), through Exclusive Commercialization and License A
GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceuticalcompany developing a pipeline ...
September2025
1 item-
Bio-Thera Strikes Strategic Deal with Jamjoom Pharma for Securing Cosentyx? Biosimilar in MENA
Guangzhou, China / Jeddah, Saudi Arabia – September 15,2025 –Bio-Thera Solutions Inc.(688177:SH), a commercial-stage bio...
More Company News
- Medicines and Healthcare products Regulatory Agency (MHRA) Approves Bio-Thera Solutions’ Qletli? (adalimumab), a biosimilar referencing Humira?
- The European Commission (EC) Approves Bio-Thera Solutions’ BAT2206 (USYMRO?, ustekinumab), a biosimilar referencing Stelara?
- Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
- Bio-Thera Solutions Announces FDA Accepts Biologics License Application for BAT2506, a Proposed Biosimilar to Simponi?
- IDMC Provides Positive Recommendation for Bio-Thera Solution’s BAT4406F (ADCC-Enhanced Anti-CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III Trial